Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

  • End date
    Mar 1, 2023
  • participants needed
  • sponsor
    Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Updated on 1 May 2022


The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.


Locally manufactured second generation autologous CD19 CAR-T cells are used for immunotherapy. Protocol treatment includes lymphodepleting conditioning (fludarabine + cyclophosphamide) followed by one CAR-T cells intravenous infusion with tocilizumab premedication.

Condition B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
Treatment Tocilizumab, CD19 CAR-T-cells
Clinical Study IdentifierNCT05333302
SponsorBelarusian Research Center for Pediatric Oncology, Hematology and Immunology
Last Modified on1 May 2022


Yes No Not Sure

Inclusion Criteria

CD19+ relapsed or refractory lymphoblastic leukemia/lymphoma
Karnofsky or Lansky performance scale greater or equal to 70
T-cells count in peripheral blood >150 cells/µL
Written informed consent

Exclusion Criteria

primary immunodeficiencies or genetic syndromes
neurologic diseases
autoimmune diseases or polyallergie
transfusion of donor lymphocyte less than 6 week before CAR-T cells infusion
GvHD grade 2-4
uncontrolled systemic infection
hypoxia (Sp02<90%)
severe hepatic dysfunction: ALT or AST >=3x upper limit of normal for age
renal dysfunction: serum creatinine level >=3x upper limit of normal for age
positive serology for human immunodeficiency virus (HIV), active hepatite C or B
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note